Core Viewpoint - The stock of Giant Bio (02367) has dropped over 4%, currently trading at 58.9 HKD with a transaction volume of 272 million HKD, following allegations regarding the quality of its collagen products [1] Group 1: Company Developments - Huaxi Bio has officially responded to the controversy surrounding Dr. Hao Yu, revealing that it has conducted tests on related products in collaboration with multiple third-party testing agencies, which indicated that the recombinant collagen content did not meet standards [1] - Huaxi Bio has submitted dozens of test reports to the National Medical Products Administration, highlighting the seriousness of the findings [1] - In May, beauty blogger Dr. Hao Yu accused Giant Bio's product "Collagen Stick" of having a recombinant collagen content of only 0.0177%, significantly below the 0.1% non-trace addition standard, and lacking the core amino acid glycine [1] Group 2: Company Responses - Giant Bio quickly denied the allegations, asserting that its products comply with regulations and that internal testing results exceed the 0.1% standard [1] - On June 1, Huaxi Bio publicly supported Dr. Hao Yu, indicating a division in the industry regarding the quality of Giant Bio's products [1] - Following a series of exchanges, on June 23, Giant Bio acknowledged that its existing quality standards, testing methods, and labeling have shown limitations in certain aspects [1]